A detailed history of Stifel Financial Corp transactions in Avid Bioservices, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 16,892 shares of CDMO stock, worth $179,561. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,892
Previous 19,365 12.77%
Holding current value
$179,561
Previous $129,000 6.98%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$6.34 - $9.28 $15,678 - $22,949
-2,473 Reduced 12.77%
16,892 $120,000
Q1 2024

May 13, 2024

SELL
$5.86 - $8.79 $6,944 - $10,416
-1,185 Reduced 5.77%
19,365 $129,000
Q4 2023

Feb 12, 2024

SELL
$4.64 - $9.56 $23,896 - $49,234
-5,150 Reduced 20.04%
20,550 $133,000
Q3 2023

Nov 13, 2023

BUY
$9.4 - $14.04 $141,940 - $212,004
15,100 Added 142.45%
25,700 $242,000
Q2 2023

Aug 14, 2023

BUY
$12.96 - $20.93 $137,376 - $221,858
10,600 New
10,600 $148,000
Q4 2019

Feb 13, 2020

SELL
$5.01 - $8.16 $174,889 - $284,849
-34,908 Closed
0 $0
Q3 2019

Nov 13, 2019

SELL
$5.07 - $7.08 $1,226 - $1,713
-242 Reduced 0.69%
34,908 $170,000
Q2 2019

Aug 14, 2019

SELL
$3.43 - $5.6 $3,423 - $5,588
-998 Reduced 2.76%
35,150 $180,000
Q1 2019

May 14, 2019

SELL
$3.56 - $4.82 $2,947 - $3,990
-828 Reduced 2.24%
36,148 $139,000
Q4 2018

Feb 13, 2019

SELL
$4.04 - $6.75 $578,701 - $966,890
-143,243 Reduced 79.48%
36,976 $139,000
Q3 2018

Nov 13, 2018

SELL
$4.28 - $7.32 $36,923 - $63,149
-8,627 Reduced 4.57%
180,219 $1.24 Million
Q2 2018

Aug 14, 2018

SELL
$3.1 - $3.93 $5,421 - $6,873
-1,749 Reduced 0.92%
188,846 $747,000
Q1 2018

May 11, 2018

BUY
$2.32 - $4.22 $442,180 - $804,310
190,595 New
190,595 $555,000

Others Institutions Holding CDMO

About Avid Bioservices, Inc.


  • Ticker CDMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,167,500
  • Market Cap $661M
  • Description
  • Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant pro...
More about CDMO
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.